Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049639 | 0.97 | SIGMAR1 (0.43) | SIGMAR1NOS3NOS1MEN1KMT2A | |
| SCHEMBL7047136 | 0.92 | SIGMAR1 (0.43) | SIGMAR1NOS3NOS1MEN1KMT2A | |
| SCHEMBL7051788 | 0.86 | SIGMAR1 (0.43) | SIGMAR1NOS3NOS1MEN1KMT2A | |
| SCHEMBL7052018 | 0.84 | SIGMAR1 (0.43) | SIGMAR1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL7048510 | 0.83 | SIGMAR1 (0.41) | SIGMAR1NOS3NOS1KDM4EALDH1A1 | |
| SCHEMBL27574371 | 0.83 | SIGMAR1 (0.49) | SIGMAR1NOS3NOS1MEN1KMT2A | |
| SCHEMBL7049218 | 0.83 | NOS3 (0.42) | SIGMAR1NOS3NOS1KDM4EALDH1A1 | |
| SCHEMBL7047154 | 0.83 | SIGMAR1 (0.41) | SIGMAR1NOS3NOS1KDM4EALDH1A1 | |
| SCHEMBL6790993 | 0.83 | DRD3 (0.40) | HTR1AHTR7 | |
| SCHEMBL7049326 | 0.82 | HSD11B1 (0.52) | SIGMAR1MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114442-A1 | Substituted piperazine derivatives as mtp inhibitors | MTTP, CETP, LIPC | SIGMAR1 671/4885NOS3 3260/4885NOS1 2214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.